Company news
Gyre Therapeutics, Inc. news in 2022
Gyre Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
December 26, 2022
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
August 31, 2022
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
August 24, 2022
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
August 18, 2022
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
August 14, 2022
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
August 9, 2022
Catalyst Biosciences Publishes New Investor Presentation
July 31, 2022
Catalyst Biosciences Announces Support from Largest Single Stockholder
July 31, 2022
Catalyst Biosciences Sends Letter to Stockholders
July 18, 2022
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
July 5, 2022
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
June 28, 2022
Catalyst Biosciences Sells Complement Portfolio for $60 Million
May 22, 2022
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
May 8, 2022
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
March 30, 2022
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
March 14, 2022
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
February 16, 2022
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
January 24, 2022